Investigation Report on China Cefuroxime Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||338980|
|出版日期||內容資訊||英文 40 Pages
|中國的Cefuroxime市場分析 Investigation Report on China Cefuroxime Market, 2010-2019|
|出版日期: 2015年09月07日||內容資訊: 英文 40 Pages||
As the second generation of cephalosporin, cefuroxime features broad antibacterial spectrum, high stability and few adverse effects which ensure its great activity against bacteria.
First developed by Glaxo Wellcom, cefuroxime entered Britain, Ireland, Germany and Italy in 1978 and the US in 1987. Due to its exact efficacy, cefuroximine has been widely used to treat infections caused by sensitive bacteria in many countries. Since the beginning of the 1990s, it has become the most popular anti-infectious agents and remained hardly susceptible to beta-lactamase even after it turned generic. And it has such dosage forms as dry suspension, tablet, capsule, dispersible tablet and injection.
Cephalosporin has developed fast since the beginning of the 21st century. Due to its widest application and best efficacy, cephalosporin has occupied an important position among anti-infectious agents. As people become increasingly aware of antibiotics, the use of injection will be gradually reduced to avoid cross infection and adverse effects. With the promotion and application of many oral drugs, dispersible tablet, effervescent tablet, sirup and solution will enjoy good market prospects.
Anti-infectious agent has been leading the medicine market especially when emergency arises. And cephalosporin, as a major variety of anti-infectious agent, occupies almost half of the market. As the most used cephalosporin, cefuroxime has reported sales increase since the appearance of its power injection. As cefuroxime is found to cross blood-brain barrier easily and exert little influence on coagulation function, it has become the first choice of carniocerebral department.
According to CRI's market survey, the sales value of cefuroxime in sample hospitals rose from over CNY 400 million in 2010 to over 600 million in 2014 and CAGR during this period exceeded 10%. ESSETI (Italy), GlaxoSmithKline (Italy), Medochemie Ltd. (Cyprus), SCCPC and GlaxoSmithKline plc. occupy the market, among which ESSETI (Italy) had the largest market share of about 28% for sales value in 2014.
Due to its wide application, cefuroxime will enjoy a vast market in future.
Readers can get at least the following information through this report:
The author suggests the following groups of people purchase this report: